This finding is expected to encourage the development of new therapeutic strategies that are more effective for controlling KNF

Oct 13, 2025 by ludoplayers7.com 130 views

Expression of Peroxisome Proliferator Activator Gamma Receptor (PParγ) in Patients with Nasopharyngeal Carcinoma in H. Adam Malik Hospital

Introduction

Nasopharyngeal carcinoma (KNF) is a type of cancer that is often detected at an advanced stage due to initial symptoms that are not typical and hidden tumor location. According to the 2007 health profile data from the Ministry of Health, KNF was included in the 10 most types of cancer in Indonesia in the period 2004-2006 and the number of sufferers continued to increase. The search for new therapeutic targets for KNF is an urgent need, and the role of Peroxisome Proliferator Activator Gamma Receptor (PParγ) in the development of cancer has been a subject of interest in recent years. PParγ is a member of a nuclear receptor family who has a variety of biological functions, including in the process of adipocyte cell differentiation, monocyte and macrophage regulations, and has anti-inflammatory properties and inhibition of tumor cell proliferation.

Background

Several studies have shown that PPARγ can act as a tumor suppressor gene. The role of PParγ in the development of cancer has been studied in various types of cancer, including breast, colon, and prostate cancer. However, the expression of PParγ in patients with nasopharyngeal carcinoma has not been well studied. This study aims to determine the expression of PParγ in patients with nasopharyngeal carcinoma in H. Adam Malik Hospital.

Methodology

This research was conducted with a descriptive cross-sectional approach, involving 30 KNF samples examined by PParγ's expression with the immunohistochemical method. The samples were collected from patients with nasopharyngeal carcinoma who underwent surgery at H. Adam Malik Hospital. The expression of PParγ was analyzed using the immunohistochemical method, and the results were compared with the clinical characteristics of the patients.

Results

The results showed that KNF sufferers were most commonly found in men (70%), 41-60 years old age groups (63.3%), and non-Keratinizing Squamous Cell Carcinoma types (53.3%). Statistical analysis using the Fisher's Exact Test shows a significant relationship between PParγ expression and lymph nodes (p = 0.031) and KNF clinical stage (p = 0.028). However, no significant relationship was found between PParγ's expression and primary tumor size (p = 0.160).

Discussion

This study shows that PParγ, specifically the PParγ overexpression, is often found in Squamous Cell Carcinoma cancer in the head and neck. These results reinforce the role of PParγ in the development of cancer, especially KNF. The findings that PParγ's expression has a significant relationship with the size of the lymph nodes and the KNF clinical stage shows the potential of PParγ as a new therapy target for KNF.

Conclusion

This study provides valuable information about the role of PParγ in the development of KNF, but further research is still needed to understand the molecular mechanisms that underlie the relationship between PParγ expression and the development and dissemination of KNF. This finding is expected to encourage the development of new therapeutic strategies that are more effective for controlling KNF.

Future Directions

Further research is needed to understand the molecular mechanisms that underlie the relationship between PParγ expression and the development and dissemination of KNF. This includes studying the role of PParγ in the regulation of cell proliferation and apoptosis in nasopharyngeal carcinoma cells. Additionally, the development of new therapeutic strategies that target PParγ is an area of interest for future research.

Limitations

This study has several limitations. The sample size was relatively small, and the study was conducted in a single hospital. Additionally, the study only examined the expression of PParγ in patients with nasopharyngeal carcinoma and did not investigate the role of PParγ in other types of cancer.

Conclusion

In conclusion, this study provides valuable information about the role of PParγ in the development of KNF. The findings of this study show that PParγ is a potential new therapy target for KNF, and further research is needed to understand the molecular mechanisms that underlie the relationship between PParγ expression and the development and dissemination of KNF.
Q&A: Expression of Peroxisome Proliferator Activator Gamma Receptor (PParγ) in Patients with Nasopharyngeal Carcinoma in H. Adam Malik Hospital

Frequently Asked Questions

Q: What is the purpose of this study? A: The purpose of this study is to determine the expression of PParγ in patients with nasopharyngeal carcinoma in H. Adam Malik Hospital.

Q: What is PParγ? A: PParγ is a member of a nuclear receptor family who has a variety of biological functions, including in the process of adipocyte cell differentiation, monocyte and macrophage regulations, and has anti-inflammatory properties and inhibition of tumor cell proliferation.

Q: What is the significance of PParγ in cancer development? A: PParγ has been shown to act as a tumor suppressor gene in various types of cancer, including breast, colon, and prostate cancer.

Q: What were the results of this study? A: The results showed that KNF sufferers were most commonly found in men (70%), 41-60 years old age groups (63.3%), and non-Keratinizing Squamous Cell Carcinoma types (53.3%). Statistical analysis using the Fisher's Exact Test shows a significant relationship between PParγ expression and lymph nodes (p = 0.031) and KNF clinical stage (p = 0.028).

Q: What are the implications of this study? A: The findings of this study show that PParγ is a potential new therapy target for KNF, and further research is needed to understand the molecular mechanisms that underlie the relationship between PParγ expression and the development and dissemination of KNF.

Q: What are the limitations of this study? A: The sample size was relatively small, and the study was conducted in a single hospital. Additionally, the study only examined the expression of PParγ in patients with nasopharyngeal carcinoma and did not investigate the role of PParγ in other types of cancer.

Q: What are the future directions of this research? A: Further research is needed to understand the molecular mechanisms that underlie the relationship between PParγ expression and the development and dissemination of KNF. This includes studying the role of PParγ in the regulation of cell proliferation and apoptosis in nasopharyngeal carcinoma cells.

Q: What are the potential therapeutic applications of this research? A: The findings of this study suggest that PParγ may be a potential new therapy target for KNF. Further research is needed to develop new therapeutic strategies that target PParγ.

Additional Questions and Answers

Q: What is the relationship between PParγ expression and lymph nodes? A: The results of this study show a significant relationship between PParγ expression and lymph nodes (p = 0.031).

Q: What is the relationship between PParγ expression and KNF clinical stage? A: The results of this study show a significant relationship between PParγ expression and KNF clinical stage (p = 0.028).

Q: What is the significance of PParγ overexpression in Squamous Cell Carcinoma cancer in the head and neck? A: The findings of this study show that PParγ overexpression is often found in Squamous Cell Carcinoma cancer in the head and neck, which reinforces the role of PParγ in the development of cancer, especially KNF.

Q: What are the potential benefits of targeting PParγ in cancer therapy? A: Targeting PParγ may provide a new therapeutic strategy for controlling KNF and other types of cancer.

Conclusion

This Q&A article provides additional information about the study on the expression of PParγ in patients with nasopharyngeal carcinoma in H. Adam Malik Hospital. The findings of this study show that PParγ is a potential new therapy target for KNF, and further research is needed to understand the molecular mechanisms that underlie the relationship between PParγ expression and the development and dissemination of KNF.